BMS and Exelixis Report P-III Trial (CheckMate -9ER) Results of Opdivo (nivolumab) + Cabometyx (cabozantinib) as 1L Treatment of Advanced Renal Cell Carcinoma
Shots:
- The company reported the 3yrs. follow up results from the P-III trial (CheckMate -9ER) evaluating Opdivo + Cabometyx vs sunitinib in 651 patients
- The results showed sustained survival & response rate benefits with a median follow-up of 44.0mos., a 30% reduction in risk of death, and improvement in m-OS (49.5 vs 35.5mos.), PFS benefits were sustained with m-PFS (16.6 vs 8.4mos.), ORR benefits were maintained (55.7% vs 28.4%), responses were durable with m-DoR (23.1 vs 15.2mos.), CR rates were sustained (12.4% vs 5.2%), TRAE of any grade (97% vs 93%), grade ≥3 TRAE (67% vs 55%)
- In an exploratory biomarker analysis, m-PFS & OS were improved with 44.0mos. median follow-up regardless of PD-L1 status. The updated results will be presented at ASCO GU 2023
Ref: BMS | Image: BMS
Related News:- BMS’ Opdivo (nivolumab) Receives NICE Recommendation as 1L Treatment for Rare Gastroesophageal Cancers
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
